Gladstone Institutional Advisory’s Fortress Biotech FBIO Stock Holding History

Gladstone Institutional Advisory’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,000	Closed	-$21.7K	–	709
2024 Q3	$21.7K	Sell	15,000 -6,500	-30%	-$12.4K	﹤0.01%	680
2024 Q2	$36.8K	Buy	21,500 +10,000	+87%	+$18.1K	﹤0.01%	652
2024 Q1	$23K	Sell	11,500 -500	-4%	-$995	﹤0.01%	637
2023 Q4	$36.1K	Buy	+12,000	New	+$31.7K	﹤0.01%	658
2021 Q4	–	Sell	-729	Closed	-$35K	–	612
2021 Q3	$35K	Hold	729	–	–	﹤0.01%	537
2021 Q2	$39K	Hold	729	–	–	﹤0.01%	513
2021 Q1	$39K	Hold	729	–	–	0.01%	413
2020 Q4	$35K	Sell	729 -34	-4%	-$1.47K	0.01%	295
2020 Q3	$46K	Buy	763 +67	+10%	+$3.41K	0.01%	264
2020 Q2	$28K	Hold	696	–	–	0.01%	240
2020 Q1	$20K	Buy	+696	New	+$23.1K	0.01%	264

Other funds holding FBIO

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Gladstone Institutional Advisory's FBIO Position: Q4 2024 in Review

Gladstone Institutional Advisory sold out of Fortress Biotech (FBIO) in Q4 2024, closing a stake of 15,000 shares — an estimated $21.7K sold.

Gladstone Institutional Advisory first reported a position in FBIO in Q1 2020 and held it in 11 quarters. The position peaked at $46K in Q3 2020. 53 funds tracked by Wall St. Rank hold FBIO as of Q4 2024.

Gladstone Institutional Advisory reported no remaining Fortress Biotech position as of Q4 2024 after selling out during the quarter.
Gladstone Institutional Advisory sold 15,000 Fortress Biotech shares in Q4 2024, an estimated $21.7K.
Gladstone Institutional Advisory first reported a position in Fortress Biotech in Q1 2020 and held it in 11 quarters.
Gladstone Institutional Advisory's Fortress Biotech position peaked at $46K in Q3 2020.
53 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2024.

Based on Gladstone Institutional Advisory's 13F filing for Q4 2024, filed 29 Jan 2025.